INVO Bioscience, Inc. (INVO) - חוב להון עצמי

This price chart illustrates the price action of INVO Bioscience, Inc. (INVO), which mitigates risks in the reproductive medicine sector by producing embryo maturation equipment and expanding its reach across specialized centers. The debt-to-equity ratio is 3.81. The business generates revenue through the sale of high-margin disposable components for the INVOcell system, despite production costs. Stable income is secured through the establishment of its own clinic network and vertical integration.

To objectively assess credit risk, it is essential for a manager to understand the financing structure, where the total liabilities-to-equity ratio determines the business's degree of dependence on borrowed funds. By analyzing the historical total debt-to-equity ratio, an investor evaluates the financial stability of INVO Bioscience, Inc., whose independence from macroeconomic trends and stable demand for medical developments allow for the effective balancing of leverage.